Portage Biotech (PRTG) Competitors $5.86 +0.02 (+0.34%) Closing price 07/3/2025 01:19 PM EasternExtended Trading$5.87 +0.01 (+0.15%) As of 07/3/2025 04:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRTG vs. CYTH, BCAB, OVID, FBLG, CVKD, ALXO, NNVC, CALC, GBIO, and CMMBShould you be buying Portage Biotech stock or one of its competitors? The main competitors of Portage Biotech include Cyclo Therapeutics (CYTH), BioAtla (BCAB), Ovid Therapeutics (OVID), FibroBiologics (FBLG), Cadrenal Therapeutics (CVKD), ALX Oncology (ALXO), NanoViricides (NNVC), CalciMedica (CALC), Generation Bio (GBIO), and Chemomab Therapeutics (CMMB). These companies are all part of the "pharmaceutical products" industry. Portage Biotech vs. Its Competitors Cyclo Therapeutics BioAtla Ovid Therapeutics FibroBiologics Cadrenal Therapeutics ALX Oncology NanoViricides CalciMedica Generation Bio Chemomab Therapeutics Cyclo Therapeutics (NASDAQ:CYTH) and Portage Biotech (NASDAQ:PRTG) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation. Which has more risk & volatility, CYTH or PRTG? Cyclo Therapeutics has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Do insiders & institutionals believe in CYTH or PRTG? 68.6% of Cyclo Therapeutics shares are owned by institutional investors. Comparatively, 13.4% of Portage Biotech shares are owned by institutional investors. 29.8% of Cyclo Therapeutics shares are owned by insiders. Comparatively, 42.1% of Portage Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CYTH or PRTG more profitable? Portage Biotech has a net margin of 0.00% compared to Cyclo Therapeutics' net margin of -2,847.19%. Company Net Margins Return on Equity Return on Assets Cyclo Therapeutics-2,847.19% N/A -307.16% Portage Biotech N/A N/A N/A Do analysts rate CYTH or PRTG? Cyclo Therapeutics presently has a consensus price target of $0.95, indicating a potential upside of 31.83%. Given Cyclo Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe Cyclo Therapeutics is more favorable than Portage Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cyclo Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Portage Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media prefer CYTH or PRTG? In the previous week, Cyclo Therapeutics' average media sentiment score of 0.00 equaled Portage Biotech'saverage media sentiment score. Company Overall Sentiment Cyclo Therapeutics Neutral Portage Biotech Neutral Which has higher valuation & earnings, CYTH or PRTG? Cyclo Therapeutics has higher revenue and earnings than Portage Biotech. Cyclo Therapeutics is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCyclo Therapeutics$870.73K27.24-$20.06M-$0.90-0.80Portage BiotechN/AN/A-$75.34M-$41.65-0.14 SummaryCyclo Therapeutics beats Portage Biotech on 7 of the 12 factors compared between the two stocks. Get Portage Biotech News Delivered to You Automatically Sign up to receive the latest news and ratings for PRTG and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PRTG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRTG vs. The Competition Export to ExcelMetricPortage BiotechMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.94M$2.91B$5.56B$9.04BDividend YieldN/A2.44%5.22%3.99%P/E Ratio-0.1421.5627.6620.25Price / SalesN/A283.36423.00177.43Price / Cash0.7042.7336.8958.10Price / Book1.577.518.035.67Net Income-$75.34M-$55.14M$3.18B$249.21M7 Day Performance5.78%4.61%2.93%3.28%1 Month Performance-30.32%0.90%1.72%3.95%1 Year Performance94.04%5.40%34.39%20.98% Portage Biotech Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRTGPortage Biotech0.6665 of 5 stars$5.86+0.3%N/A+94.0%$5.94MN/A-0.146CYTHCyclo TherapeuticsN/A$0.72flat$0.95+31.8%N/A$23.72M$870.73K-0.809BCABBioAtla2.6981 of 5 stars$0.41+2.3%$5.00+1,134.6%-71.2%$23.66M$11M-0.3360News CoverageGap DownOVIDOvid Therapeutics4.3742 of 5 stars$0.33-1.2%$3.13+858.6%-53.9%$23.18M$570K-0.9360FBLGFibroBiologics2.2982 of 5 stars$0.60-2.9%$13.00+2,052.3%-87.0%$23.11MN/A-2.8810Gap UpCVKDCadrenal Therapeutics2.8547 of 5 stars$11.69-3.0%$32.00+173.9%N/A$23.02MN/A-1.264Positive NewsGap UpALXOALX Oncology2.6459 of 5 stars$0.43+4.3%$3.30+662.1%-91.4%$23.02MN/A-0.1740Negative NewsNNVCNanoViricides1.0934 of 5 stars$1.40flatN/A-20.0%$22.50MN/A-1.9420Gap DownCALCCalciMedica3.0917 of 5 stars$1.59-0.9%$18.00+1,035.6%-61.8%$22.15MN/A-1.0230Gap UpGBIOGeneration Bio2.9681 of 5 stars$0.33+2.5%$7.33+2,135.8%-83.9%$21.99M$19.89M-0.30150CMMBChemomab Therapeutics2.9051 of 5 stars$1.16flat$8.50+632.8%+19.8%$21.88MN/A-1.5320 Related Companies and Tools Related Companies Cyclo Therapeutics Alternatives BioAtla Alternatives Ovid Therapeutics Alternatives FibroBiologics Alternatives Cadrenal Therapeutics Alternatives ALX Oncology Alternatives NanoViricides Alternatives CalciMedica Alternatives Generation Bio Alternatives Chemomab Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRTG) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredJuly 4th: 59% dividend from Bitcoin (No Crypto Needed)I've got something exciting for you this July 4th holiday... How about a 59.07% dividend from Bitcoin? Y...Investors Alley | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump's ticking time bombA looming tariff deadline on July 9th could be the spark — but what’s buried inside a recent White House docum...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Portage Biotech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Portage Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PRTG Stock Alerts